EGFR mutations are among the most common alterations in lung cancer. In advanced disease, the rapid identification of these mutations in liquid biopsies and small tumor tissue samples would allow expedited stratification, and aid in the identification of samples that would benefit from more comprehensive assessment.
In this educational webinar, Dr. Maria Arcila of Memorial Sloan Kettering Cancer Center will discuss the following:
- The growing importance of liquid biopsy assays as part of a lung cancer testing algorithm
- Updated lung cancer testing recommendations
- Selection of an EGFR testing methodology compatible with flexible sample types including small biopsies, cytological samples, and cell-free DNA
- Implementation of rapid, single-gene testing for lung cancer specimens to complement broad next-generation sequencing panels
